Journals / Türk Toraks Dergisi / 2011 / Cilt: 12 - Sayı: 4

Can brain natriuretic peptide (bnp) be a predictor for pulmonary arterial hypertension?

Plazma b - natriüretik peptid (bnp) düzeyi kronik akciğer hastalıklarında pulmoner hipertansiyon için gösterge olabilir mi?

Pages
134–138
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In the subgroup analysis, a significant relationship was found between BNP and pulmonary arterial pressure in chronic PE and ILD groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Brain Natriuretic Peptide (BNP), which is a neuropeptide, is produced and released from the ventricles in response to increased wall stretch and tension.
📊
Key Findings & Data:A total of 104 patients, who were regularly followed in the outpatient clinic, were included in this study.
💡
Conclusion & Impact:Conclusion: In the subgroup analysis, a significant relationship was found between BNP and pulmonary arterial pressure in chronic PE and ILD groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Brain Natriuretic Peptide (BNP), which is a neuropeptide, is produced and released from the ventricles in response to increased wall stretch and tension. The level of BNP is high in patients with congestive heart failure and even in asymptomathic patients with left ventricle disfunction. There is no adequate literature about the value of BNP in chronic lung diseases such as interstitial lung disease (ILD), chronic pulmonary embolism (PE), chronic obstructive pulmonary disease (COPD) and chronic respiratory failure due to COPD. Material and Method: We investigated the value of BNP in chronic lung diseases, and BNP as a predictor for pulmonary arterial pressure (PAP) levels and right heart failure. A total of 104 patients, who were regularly followed in the outpatient clinic, were included in this study. Twenty-six of them had COPD (FEV1<50%), 21 had chronic PE, 33 had respiratory failure due to COPD and 24 had ILD. Spirometry, DLCO, arterial blood gas analysis, six minute walking test, echocardiography and plasma BNP level measurements were performed in all of the patients. Pearson&#8217;s correlation test, linear regression analysis and t test were used for statistical analysis. Results: There were 67 male and 37 female patients and the mean age was 57.6 years. BNP showed a negative correlation with 6-min walk distance (r=-0.204, p=0.045), and positive correlation with PAP (r=0.351, p<0.001). Conclusion: In the subgroup analysis, a significant relationship was found between BNP and pulmonary arterial pressure in chronic PE and ILD groups.

Özet

Amaç: BNP kardiyak volüm ve basınç artışına cevap olarak ventriküllerden salınan bir nöropeptiddir. Bu nedenle konjestif kalp yetmezliğinde, hatta asemptomatik sol ventrikül sistolik disfonksiyonunda BNP normal değerlerin üzerinde saptanır. İntertisyel akciğer hastalığı (İAH), kronik pulmoner emboli (PE), ağır KOAH ve kronik solunum yetersizliği (SY) gibi kronik akciğer hastalıklarında BNP’nin değeri net olarak ortaya konulmamıştır. Gereç ve Yöntem: Plazma BNP düzeyinin kronik akciğer hastalıklarındaki yerini araştırmak ve bu olgularda BNP`nin pulmoner arter basıncı (PAB) ve sağ kalp yetmezliği için bir belirteç olup olmadığını değerlendirmek. Çalışmaya kronik akciğer hastalığı nedeniyle poliklinikten takip edilen stabil 104 olgu (26 ağır KOAH, 21 kronik pulmoner emboli, 24 intertisyel akciğer hastalığı ve 33 KOAH’a bağlı kronik solunum yetersizliği) alındı. Tüm olgulara solunum fonksiyon testi, difüzyon testi, arter kan gazı analizi, altı dakika yürüme testi, ekokardiyografi ve plazma BNP ölçümü yapıldı. İstatistiksel analiz için Pearson korelasyon testi, lineer regresyon analizi ve t test kullanıldı. Bulgular: Olguların 37’si kadın, 67’si erkek ve yaş ortalaması 57.6 yıl idi. BNP düzeyi ile yürüme mesafesi arasında negatif (r=-204, p=0.045), PAB ile pozitif korelasyon (r=0.351, p<0.001) bulundu. Alt grup analizlerine bakıldığında ise yalnızca PE ve İAH gruplarında, PAB ile BNP arasında (p<0.01; p<0.03) anlamlı ilişki saptandı. Sonuç: Çalışmamızda plazma BNP düzeyi, perfüzyon defektleri devam eden kronik PE ve İAH olgularında PAB düzeyi ile ilişkili olarak saptanırken; ağır KOAH ve SY olgularında bu ilişki saptanmadı.

🔖

Cite This Article

OKUMUŞ, G., KIYAN, E., BİLGE, A. K., BİNGÖL, Z., ÇÖMÇE, F., BOLAYIR, M., ASLAN, G. K., KIYAN, A., TABAK, L., ARSEVEN, O. (2011). Can brain natriuretic peptide (bnp) be a predictor for pulmonary arterial hypertension?. Türk Toraks Dergisi, Cilt: 12 - Sayı: 4, 134–138. https://ajindex.com/articles/329588

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. King L, Wilkins MR. Natriuretic peptide receptors and the heart. Heart 2002;87:314-5. [CrossRef] 2. Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998;135:914-23. [CrossRef] 3. Maisel A, Krishnaswamy P, Nowak R, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. [CrossRef] 4. Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362: 316-22. [CrossRef] 5. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37: 379-85. [CrossRef] 6. Silver M, Maisel A, Yancy C, et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004;10:1-30. [CrossRef] 7. Lang CC, Coutie WJ, Sthurders AD, et al. Elevated levels of BNP in in acute hypoxemic COPD. Clin Sci 1992;83:529-33. 8. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-8. [CrossRef] 9. Pruszczyk P, Kostrubiec M, Bochowicz A, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003;22:649-53. [CrossRef] 10. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-70. [CrossRef] 11. Januzzi J, Camargo C, Anwaruddin S, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol 2005;95:948-54. [CrossRef] 12. Bozkanat E, Tozkoparan E, Baysan O, et al. The Significance of Elevated Brain Natriuretic Peptide Levels in Chronic Obstructive Pulmonary Disease. The Journal of International Medical Research 2005;33:537-44. 13. Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med. 2009;48:503-12. [CrossRef] 14. Bando M, Ishii Y, Sugiyama Y, et al. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999;93:507-14. [C